
Chronic pain often persists after the initial injury, inflammation, or tissue stress has subsided, suggesting that sustained cellular and microenvironmental changes contribute to pain chronification. Cellular senescence may be one of the mechanisms linking persistent tissue stress with neuroinflammation and altered pain processing. Senescence or senescence-like changes have been reported in nociceptors, dorsal root ganglion neurons, glial cells, immune cells, and local tissue-resident cells in several chronic pain conditions. These changes may influence pain through senescence-associated secretory phenotype (SASP)-related signaling, which can sustain inflammation, increase nociceptor excitability, promote glial activation, and contribute to peripheral and central sensitization. The available evidence, however, is not equally strong across pain conditions. Neuropathic pain and some degenerative nociceptive pain models provide relatively direct evidence, including senescence-related phenotypes and improvement after senolytic treatment. In nociplastic pain, glial and neuroimmune changes overlap with mechanisms associated with senescence, but direct evidence of cellular senescence remains limited. Evidence in bone cancer pain is also mainly indirect, as many inflammatory mediators and signaling pathways overlap with SASP biology without demonstrating that they originate from senescent cells. This review discusses these differences in evidence and examines the possible value of senolytic and senomorphic strategies in chronic pain. Further studies are needed to identify relevant senescent cell populations, establish reliable biomarkers, and clarify treatment timing, safety, and off-target effects before these approaches can be translated into clinical practice.
Background Visceral pain in inflammatory bowel disease (IBD) lacks effective therapies. Whether the TREM1/DAP12 pathway is associated with electroacupuncture (EA) analgesia and cortical EEG modulation remains unclear. Objective To determine if spinal TREM1/DAP12 is associated with EA’s analgesic and neuromodulatory effects in TNBS-induced visceral pain. Methods Male Sprague-Dawley rats with TNBS-induced colitis received EA (ST36/ST37), the TREM1 inhibitor Nangibotide, or their combination. Behaviors (PWT, CRD, DAI), spinal TREM1/DAP12, downstream inflammatory mediators, and microglial colocalization were evaluated. Cortical EEG was analyzed using normalized power spectral density (Normalized PSD, %). Results EA significantly alleviated visceral/referred hyperalgesia and reduced DAI scores ( P < 0.05). TNBS upregulated spinal TREM1, DAP12, TNF-α, NLRP3, and TLR4 and increased TREM1/DAP12 microglial colocalization ( P < 0.0001), all reversed by EA (P < 0.001). Nangibotide alone partially mimicked EA’s effects, and their combination yielded greater analgesia and molecular suppression ( P < 0.05). Normalized EEG analysis revealed that TNBS increased δ power ( P < 0.0001) and reduced θ and β power ( P < 0.001). Notably, EA and Nangibotide specifically reversed δ elevation and restored θ power ( P <0.05) without altering β power ( P > 0.05), with greater δ suppression than either treatment alone ( P < 0.0001). Conclusion EA alleviates TNBS visceral pain and normalizes cortical δ/θ dysrhythmia, with these effects associated with suppression of microglial TREM1/DAP12 neuroinflammation. Pharmacological TREM1 blockade mimics and enhances EA’s effects, supporting this pathway as a promising therapeutic target for visceral pain.
Objective To evaluate whether genetically proxied leukocyte telomere length (TL), a systemic marker of biological aging and cumulative cellular stress, is associated with trigeminal neuralgia (TN) risk. Background TN is a severe craniofacial pain disorder classically attributed to neurovascular compression and focal trigeminal root demyelination. However, comparable neurovascular anatomy does not always produce symptoms, suggesting that host-level biological vulnerability may influence susceptibility. Methods We performed a two-sample Mendelian randomization study using genome-wide significant single nucleotide polymorphisms for leukocyte TL as genetic instruments. The outcome was FinnGen ICD-10 G50.0 trigeminal neuralgia. Primary analysis used inverse variance weighting (IVW), with MR-Egger, weighted median, weighted mode, and MR-PRESSO as complementary estimators. Sensitivity analyses included Steiger filtering, pleiotropy testing, heterogeneity testing, and leave-one-out analysis. Reverse MR, exploratory multivariable MR, and comparator analyses for atypical facial pain, migraine, and polyneuropathy were performed. Results Longer genetically proxied TL was associated with lower TN risk using IVW MR (OR=0.732, p=0.008). Results were concordant across weighted median (OR=0.606, p=0.011), weighted mode (OR=0.577, p=0.017), and MR-PRESSO (OR=0.732, p=0.008), while MR-Egger was directionally consistent but nonsignificant (OR=0.671, p=0.055). Steiger-filtered IVW remained directionally consistent but attenuated to non-significance while Reverse MR was non-significant. The TL-TN association remained directionally consistent after exploratory multivariable MR conditioning and was not observed for comparator phenotypes. Conclusion Longer genetically proxied leukocyte TL was associated with lower TN risk. These findings identify leukocyte telomere length as a candidate systemic aging-related susceptibility marker for trigeminal neuralgia and support further studies integrating telomere biology with neurovascular compression grading, trigeminal nerve morphometry, and clinical outcomes.
Background: Both depressive and pain symptoms are highly prevalent and relevant comorbid conditions in Veterans with Gulf War Illness (GWI). This study assessed how the severity of depressive symptoms may affect supraspinal pain modulatory functional connectivity (FC) in Veterans with GWI-related chronic Headache And body, muscle, and joint Pain conditions (GWI-HAP) and how depressive symptoms alone or paired with pain symptomology or other neuropsychological and functional assessments were able to predict supraspinal functional connectivity (FC) relevant to pain modulation. Methods: Resting state functional MRI (rs-fMRI) conducted in Veterans with GWI-HAP and moderate to severe depressive symptoms reflected by the Hamilton Rating Scale for Depression (HRSD) score <14(GWI ≥ 14) and their counterparts with no or mild depressive symptoms (GWI<14) were compared along with pain symptomology, functional, quality of life, and Post-Traumatic Stress Disorder assessments. Results: Region of interest (ROI)-to-ROI rs-fMRI FC analyses indicated the GWI ≥ 14 group (N=33) showed significantly enhanced FC of the left dorsolateral prefrontal cortex (DLPFC) with the contralateral Insula (BA 13; P < 0.001; T= 7.14), visuomotor cortex (BA7, P<0.01, T=4.82) and two regions of contralateral thalamus (P < 0.01, P < 0.001; T= 5.32, T= 5.25, respectively); and decreased FC with the ipsilateral premotor cortex (BA 6; P < 0.01; t = -3.34) and contralateral anterior cingulate cortex (BA 32; P < 0.001; T= -3.64) than the GWI<14 group (N=33). Independent T-tests also indicated that the GWI ≥ 14 group demonstrated a significantly (P<0.05) higher level of pain severity, functional, and quality of life impairments, and PTSD symptomology in comparison with the GWI<14 group. Stepwise regression analyses of the combined group indicated that despite the detected significant between-group difference in supraspinal FC of the left DLPFC to other pain-relevant supraspinal regions, either the degree of depressive symptoms or any other study assessment was able to reliably predict the FC of the left DLPFC to the right ACC. In addition, other assessments alone did not reliably predict the left DLPFC to other pain relevant ROI. However, adding other pain symptomology, neuropsychological, and functional assessments to depressive symptom severity assessment can enhance the prediction of the supraspinal FC relevant to pain modulation. Conclusions: While significant between-group differences in supraspinal modulatory FC were found based on the severity of depressive symptoms, pain symptomology, functional, and quality of life impairments, these assessments alone did not predict the FC correlation of left the DLPFC in most detected ROI differences. However, individually pairing mood with other pain and functional assessments can enhance the prediction of the underlying supraspinal pain modulatory FC. Potential non-invasive brain stimulation interventions such as TMS with various treatment targeting options, which are applicable for addressing these highly prevalent co-morbid conditions and functional impairments, may incorporate this mechanistic correlation and prediction in formulating a corresponding therapeutic strategy.
The most burdensome symptom of temporomandibular joint disorders (TMJDs) is mechanically evoked pain. To identify the trigeminal ganglion (TG) neuronal subtypes mediating mechanical sensitivity, we combined whole-cell patch-clamp electrophysiology with immunohistochemistry (IHC) to characterize mouse TMJ-innervating TG neurons retrogradely labeled from the TMJ. Electrophysiological analysis identified five distinct neuronal groups, only one of which responded to piezo actuator-induced mechanical stimulation. TMJ innervation was dominated by C- and A-nociceptors, comprising four of the five identified groups. The fifth, a minor population of small-diameter neurons (S1), displayed properties consistent with either vGlut3-positive, C-low-threshold mechanoreceptors (C-LTMRs) or Sst-positive neurons. Two mechanically insensitive C-nociceptor groups, distinguished by their action potential firing patterns, likely corresponded to CGRP-positive and non-Mrgpr neuronal populations. One mechanically insensitive A-nociceptor group likely represented Smr2-positive Aδ high-threshold mechanoreceptors (Aδ-HTMRs). The only mechanically responsive neurons were large-diameter A-nociceptors, which likely correspond to the weakly TrkC- expressing neuronal population. No recorded neurons displayed electrophysiological characteristics of classical A-LTMRs. Together, these findings demonstrate that the TMJ is innervated by a distinct repertoire of TG sensory neurons compared with the skin and masseter muscle, with mechanically responsive afferents restricted to a single A-nociceptor subtype rather than classical low-threshold mechanoreceptors.